Despite great progress in the identifications of genes associated with breast cancer, there is still limited use of such knowledge in breast cancer (BC) screening, with nearly one-third of BC patients still missing the early detection phase. We have developed BRECARDA, an AI-based framework that incorporates genetic information and clinical risk factors to predict breast cancer risk. BRECARDA achieved good performance when evaluated with a real-world clinical dataset. This BRECARDA framework can be broadly applied to the general population, making risk assessment more accessible. It has the potential to advance early detection. (https://jmg.bmj.com/content/early/2023/04/12/jmg-2022-108582 )